Generics US generics major Actavis (NYSE: ACT, the new name for the Watson business) reported net revenue increased 13% to $1.75 billion for the fourth quarter 2012, compared to $1.54 billion in the fourth quarter 2011, slightly higher than analysts' expectations of $1.74 billion. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2012 was $1.59, compared to $1.77 per diluted share in the fourth quarter 2011, a decline of 10%, but still beat the forecasts of $1.53 of 20 analysts polled by Thomson Reuters. 19 February 2013